drugset / Trial / NCT04995484
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment.
Timeline
- Start
- 2022-06-24
- Primary completion
- 2023-12-25
- Completion
- 2024-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belzutifan | Small molecule | 80 mg | Oral |
Indications
No indication recorded.